A detailed history of Morgan Stanley transactions in Compass Pathways PLC stock. As of the latest transaction made, Morgan Stanley holds 44,614 shares of CMPS stock, worth $381,003. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,614
Previous 40,176 11.05%
Holding current value
$381,003
Previous $343,000 11.08%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
N/A
4,438 Added 11.05%
44,614 $381,000
Q4 2023

Feb 13, 2024

SELL
N/A
-21,051 Reduced 34.38%
40,176 $343,000
Q3 2023

Nov 15, 2023

SELL
N/A
-18,739 Reduced 23.43%
61,227 $522,000
Q2 2023

Aug 14, 2023

SELL
$7.79 - $10.69 $94,134 - $129,177
-12,084 Reduced 13.13%
79,966 $682,000
Q1 2023

May 15, 2023

SELL
$7.32 - $10.85 $1.72 Million - $2.55 Million
-234,790 Reduced 71.84%
92,050 $914,000
Q4 2022

Feb 14, 2023

SELL
$7.84 - $11.68 $457,542 - $681,644
-58,360 Reduced 15.15%
326,840 $2.62 Million
Q3 2022

Nov 14, 2022

SELL
$10.73 - $20.07 $1.14 Million - $2.13 Million
-106,282 Reduced 21.62%
385,200 $4.13 Million
Q2 2022

Oct 27, 2022

SELL
$6.76 - $14.18 $2.27 Million - $4.75 Million
-335,214 Reduced 40.55%
491,482 $5.32 Million
Q2 2022

Aug 15, 2022

SELL
$6.76 - $14.18 $2.27 Million - $4.75 Million
-335,214 Reduced 40.55%
491,482 $5.32 Million
Q1 2022

Oct 27, 2022

BUY
$11.13 - $23.04 $3.73 Million - $7.72 Million
335,214 Added 68.2%
826,696 $10.7 Million
Q1 2022

May 13, 2022

BUY
$11.13 - $23.04 $2.22 Million - $4.6 Million
199,592 Added 31.83%
826,696 $10.7 Million
Q4 2021

Feb 14, 2022

BUY
$21.81 - $48.96 $11.5 Million - $25.8 Million
526,139 Added 521.11%
627,104 $13.9 Million
Q3 2021

Nov 15, 2021

BUY
$29.03 - $38.62 $2.93 Million - $3.9 Million
100,965 New
100,965 $3.02 Million

Others Institutions Holding CMPS

About COMPASS Pathways plc


  • Ticker CMPS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Care Facilities
  • Shares Outstandng 42,522,400
  • Market Cap $363M
  • Description
  • COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. Th...
More about CMPS
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.